The four core advantages of tielpotide
Dual targets lead to more significant weight loss effects
Tilarpotide collaboratively regulates appetite, calorie intake and metabolic function by simultaneously activating GIP and GLP-1 receptors. GLP-1 delays gastric emptying and supposes appetite, while GIP enhances fat metabolism. By taking these two approaches simultaneously, the effect of “eating less + burning fat quickly” is achieved.
Data support: Head-to-head studies show that the average weight loss of tielpotide is 47% higher than that of semaglutide, with a 72-week weight loss of 20.2% vs. 13.7%.
2. Clinical trial data set a record
Surmoun-1 trial: Obese patients in the 15mg dose group lost an average of 22.5% (approximately 24 kilograms) of weight, setting a record of more than 20% weight loss in the phase III trial.
SURMOUNT-3 trial: After 84 weeks of treatment, the average weight loss of the patients reached 26.6% (approximately 29.2 kilograms), setting a new record for drug weight loss.
Significant reduction in waist circumference: The average waist circumference in the high-dose group decreased by 19.4 centimeters, and the improvement of abdominal obesity was more obvious.
3. Multi-system health benefits
Cardiovascular protection: Studies have shown that tielpotide can reduce the risk of cardiovascular death in patients with heart failure by 38% and improve cardiac function indicators.
Improving sleep apnea: Among obese patients with sleep apnea, the apnea-hypopnea index (AHI) decreased by more than 50% after tielpotide treatment, and the symptoms of some patients were completely relieved.
Prevention of diabetes: After use by patients with prediabetes, the risk of new-onset type 2 diabetes was reduced to 1.3% (placebo)
4. It has relatively high safety and controllable side effects
The common side effects are mild to moderate gastrointestinal reactions such as nausea and diarrhea, which mostly occur in the early stage of medication and gradually subside with the extension of treatment time. Long-term studies have not found serious safety hazards, and patients have good tolerance.
Reminders for Scientific Medication Use
Applicable population: Individuals with a BMI of 28 or above (obese) or a BMI of 24 or above (overweight) and accompanied by complications such as hypertension and diabetes.
2. Medication should follow the doctor’s advice: It is necessary to rule out contraindications such as pancreatitis and thyroid tumors, and regularly monitor physical indicators.
3. Cooperate with lifestyle adjustments: Medication is not a “magic needle”. It should be combined with diet control and exercise to avoid rebound after stopping the medication.
Tielpotide, with its dual-target mechanism, record-breaking weight loss data and multi-dimensional health benefits, is leading a new era in obesity treatment. However, weight loss still requires scientific planning. Medication is a tool rather than an end point. In the future, as more research progresses, tielpotide may bring a glimmer of hope for health to more obese patients!
Post time: Jun-06-2025